CA2033984A1 - Method for the production of human monoclonal antibodies - Google Patents
Method for the production of human monoclonal antibodiesInfo
- Publication number
- CA2033984A1 CA2033984A1 CA 2033984 CA2033984A CA2033984A1 CA 2033984 A1 CA2033984 A1 CA 2033984A1 CA 2033984 CA2033984 CA 2033984 CA 2033984 A CA2033984 A CA 2033984A CA 2033984 A1 CA2033984 A1 CA 2033984A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell precursors
- antigen
- medium
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000002243 precursor Substances 0.000 claims abstract description 65
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 60
- 239000000427 antigen Substances 0.000 claims abstract description 32
- 108091007433 antigens Proteins 0.000 claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 32
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 241000700605 Viruses Species 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 238000002955 isolation Methods 0.000 claims abstract description 11
- 230000004913 activation Effects 0.000 claims abstract description 9
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 8
- 238000010367 cloning Methods 0.000 claims abstract description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 8
- 208000016361 genetic disease Diseases 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 210000004224 pleura Anatomy 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000028782 Hereditary disease Diseases 0.000 abstract description 2
- 208000024556 Mendelian disease Diseases 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 41
- 239000007850 fluorescent dye Substances 0.000 description 21
- 239000000975 dye Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000004180 plasmocyte Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000003297 immature b lymphocyte Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 210000005033 mesothelial cell Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XJKSTNDFUHDPQJ-UHFFFAOYSA-N 1,4-diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=C(C=2C=CC=CC=2)C=C1 XJKSTNDFUHDPQJ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229930184652 p-Terphenyl Natural products 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP3921211.4 | 1989-06-28 | ||
| DE19893921211 DE3921211C1 (enExample) | 1989-06-28 | 1989-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2033984A1 true CA2033984A1 (en) | 1990-12-29 |
Family
ID=6383797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2033984 Abandoned CA2033984A1 (en) | 1989-06-28 | 1990-06-20 | Method for the production of human monoclonal antibodies |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0431125A1 (enExample) |
| CA (1) | CA2033984A1 (enExample) |
| DE (1) | DE3921211C1 (enExample) |
| WO (1) | WO1991000342A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| US6197299B1 (en) | 1990-07-20 | 2001-03-06 | Pharmacia & Upjohn Ab | Antibody conjugates |
| ATE243747T1 (de) * | 1991-07-15 | 2003-07-15 | Wellcome Found | Herstellung von antikörpern |
| GB9126094D0 (en) * | 1991-12-09 | 1992-02-12 | Immune Systems Ltd | In vitro antibody production |
| SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) * | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4693966A (en) * | 1983-03-11 | 1987-09-15 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies from lymphocytes of patients with malignant melanoma |
| EP0348413A1 (en) * | 1987-03-11 | 1990-01-03 | The Children's Hospital, Incorporated | Method for the generation of antigen-specific t cell lines and therapeutic use thereof |
| DE3827145A1 (de) * | 1987-12-03 | 1989-06-15 | Biotechnolog Forschung Gmbh | Monoklonale antikoerper, hybridoma-zellinien zur gewinnung der antikoerper, verfahren zur gewinnung der antikoerper und der zellinien, sowie verwendung der antikoerper |
| DE3811692A1 (de) * | 1988-04-07 | 1989-10-19 | Idt Ag Fuer In Vivo Diagnostik | Diagnostikverfahren und mittel zur diagnose und behandlung immunologischer erkrankungen |
-
1989
- 1989-06-28 DE DE19893921211 patent/DE3921211C1/de not_active Expired - Lifetime
-
1990
- 1990-06-20 EP EP19900909725 patent/EP0431125A1/de not_active Withdrawn
- 1990-06-20 CA CA 2033984 patent/CA2033984A1/en not_active Abandoned
- 1990-06-20 WO PCT/EP1990/000976 patent/WO1991000342A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE3921211C1 (enExample) | 1990-11-29 |
| EP0431125A1 (de) | 1991-06-12 |
| WO1991000342A1 (de) | 1991-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2133316C (en) | In vitro generation of human dendritic cells and uses thereof | |
| CN105754941B (zh) | 一种外周血nk细胞的体外诱导扩增培养方法 | |
| KR20010030775A (ko) | 생체외 조혈세포의 자극방법 | |
| JPS59169489A (ja) | ヒト培養株化細胞 | |
| CN110129273A (zh) | 搭载抗pd-1单链抗体的基因工程化红细胞及其制备方法 | |
| CN108103019B (zh) | 一种肿瘤特异性γδ T细胞的制备方法 | |
| CN113293132A (zh) | 一种nk细胞体外扩增体系及培养方法 | |
| EP3936611A1 (en) | Composition, culture medium and method for inducing and/or amplifying tscm in vitro | |
| CN108251378B (zh) | 一种过表达ptgds基因的间质干细胞外泌体及其制备方法和应用 | |
| CN115746137A (zh) | 一种抗cd8抗体及其应用 | |
| CA2033984A1 (en) | Method for the production of human monoclonal antibodies | |
| JP5464641B2 (ja) | 制御性ｔ細胞製造方法及び制御性ｔ細胞増幅装置 | |
| CN109234232A (zh) | 兔外周血b细胞的培养体系及培养方法、抗体的制备方法和应用 | |
| CN119144556B (zh) | 一种nk细胞的制备方法及其在治疗恶性肿瘤中的用途 | |
| CN113564117B (zh) | 一种冻存脐带血来源调节性t细胞体外扩增优化方法 | |
| CN106075626B (zh) | 一种艾滋病血液净化治疗仪 | |
| WO2022194118A1 (zh) | 一种car-t细胞灌流培养方法 | |
| CN106166313B (zh) | 一种艾滋病孕妇血液净化器 | |
| CN109321531A (zh) | 一种将外周血免疫γδT细胞诱导成多能干细胞的方法 | |
| CN112725273A (zh) | 一种nk细胞及其制备方法和应用 | |
| JP4117054B2 (ja) | 抗体及びその製法、この抗体を産生する融合細胞及びその製法、並びにこの抗体に認識される抗原蛋白質 | |
| CN100369934C (zh) | 抗人4-1bbl单克隆抗体制备及其应用 | |
| CN106267416A (zh) | 艾滋病治疗仪 | |
| CN120555351B (zh) | 一种恶性胸腹水肿瘤相关淋巴细胞的规模化细胞培养方法 | |
| CN100369933C (zh) | 抗人gl50单克隆抗体的制备及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |